Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer recently shed light on. When a caller noted that the ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Last week, President Trump sent letters to 17 major pharmaceutical companies advising them to work with his administration to ...

Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with ...

Key Points Prime Medicine posted GAAP revenue of $1.1 million, missing analyst expectations by over 70% (GAAP). Reported net loss (GAAP) narrowed to $52.6 million, driven by reduced research and ...

Emma Charles shares her vision for healthcare, how AI is reshaping pharma and why access to innovation must be faster and ...

Bristol-Myers Squibb recently saw a 6.39% drop in its stock value, with weak momentum and bearish signals from technical ...

In 2017, Megan Wanzo was pursuing health care ethics, uncertain but hopeful that she was on the right path, when she attended ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

Type II cryoglobulinemic vasculitis in patients with Sjögren disease is associated with nearly a sevenfold increased risk for ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...